But it’s about to really forecast, say, beyond the end of this year, by that blend ASP is going to look, it is very digital. I’d say our assumption for the remainder of this year is that the blended ASP is going to stay around this sort of 2,300 level.
Operator: Our next question comes from Derik De Bruin with Bank of America.
Unidentified Analyst: This is John on for Derek. So I appreciate the color on the market landscape in Japan and the pricing and whatnot. I wanted to ask what you see to be the contribution from that market over the next couple of years? If you could talk about the ramp, that would be great.
Michael Bell: Yes, it’s Mike. I can take that. Yes. I mean for Japan, we were really pleased to get reimbursement coverage this quarter. And in fact, we’ve just sort of processed our first patient sample in Japan. So really positive news. In our guide for the remainder of this year for Japan, we’ve got very minimal revenue in there. And then I think, we’re hoping and expecting in 2024 that revenue starts to become material. I think when we look at Japan as an overall market, it’s a very large market. It’s probably overall half the size of the U.S. So we think this can be, over time, a significant for us. But at the moment, I think it’s a bit too early for us to be really pointing out any specific guidance for 2024 or specific years.
And on the China side, Yes, that’s really going to help power our biopharma business. The lab partnership. We’ve got there enables us to have global offerings to our biopharma partners. And so we’re very excited to hopefully soon have that lab go live and start to offer products in China. And again, it’s going to be very incremental to our biopharma business.
Unidentified Analyst: Appreciate that. And in terms of the OpEx guide, you’ve talked about the sales and marketing spend and the research spend and that makes sense. Just really specifically the G&A was sequentially up this quarter. How is that tracking for the rest of the year for that line specifically?
Michael Bell: Yes. That line is probably in the second half of the year will be maybe a little bit lower than what we saw in the first half. We saw a bit of an uptick in this most recent quarter from a legal litigation expense perspective. And we’ve just finalized the Illumina litigation that we had, we made press release on that yesterday or the day before. And so we’re hopeful that, that expense can drop off in the second half of the year and G&A should stabilize going forward.
Operator: Our next question comes from Patrick Donnelly with Citi.
Patrick Donnelly: Maybe just one on the biopharma segment, just given overall concerns on budgets of funding there. Can you guys just pull back to kurt a little bit what you’re seeing there? What we should expect on the volume side that segment for you?
Helmy Eltoukhy: I think it’s sort of in line with sort of what we highlighted at the beginning of the year that there is a little bit of sort of rejiggering in much of the pipeline some companies have some layoffs. They’re sort of deciding what areas in the therapeutic areas and the snacks. But that was all kind of factored in at the beginning of the year. So I think we’ve been pleased that we continue diversify our customer base, continue to grow volumes in this sort of challenged environment. But we also see this as an opportunity. We’re having a great conversation on growth pharma company that early looking for new areas by which to really expand some of their pipeline, and we have a very unique platform. So it’s I think this is a future year is going to be a very strong growth at.
